Incyte Lifts Annual Revenue Forecast After Settlement with CMS

Incyte Stock Hits 52-Week High - Here's Why - Incyte (NASDAQ:INCY)

Incyte (INCY) Q2 earnings beat estimates with $1.67B revenue, $3.09 EPS. Full-year sales guidance raised. Shares rally to new 52-week high.

Incyte: From Buy To Hold After A 93% Rally (Rating Downgrade) (NASDAQ:INCY)

Incyte Corporation stock hits a 52-week high on latarcibart and strong Opzelura/Zynyz sales, but valuation & Iclusig demand drive a Hold. Click for an INCY update.

Incyte lifts annual revenue forecast after settlement with CMS

July 28 (Reuters) - Drugmaker Incyte Corp reported on Tuesday higher second-quarter earnings and raised its annual revenue forecast after it settled a lawsuit with ​the U.S. government over Medicaid rebates tied ‌to eczema cream Opzelura. Here are the ...

Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates